Corifact 250 250 Unit

CORIFACT 250 is a powder for solution containing Factor XIII, used for managing bleeding disorders. This intravenous medication supports blood clotting and is manufactured by CSL Behring Canada Inc.

CORIFACT 250 is primarily used to treat bleeding disorders associated with Factor XIII deficiency. This medication helps in the clotting process, which is essential for controlling bleeding episodes. It is often prescribed for individuals who have a genetic lack of Factor XIII, a protein crucial for blood coagulation. The solution is administered intravenously to ensure effective absorption and rapid action.

Common effects of CORIFACT 250 may include localized reactions at the injection site, such as redness or swelling. Some individuals might experience mild to moderate discomfort during or after administration. It is important to monitor for any signs of allergic reactions, which can include rash, itching, or difficulty breathing. Always consult a healthcare provider if any adverse effects are observed.

CORIFACT 250 should be handled with care, ensuring proper storage and preparation to maintain its efficacy. It is crucial to follow the healthcare provider's instructions for administration and dosage. Individuals with known allergies to Factor XIII or any components of the solution should avoid using this medication. Always inform your healthcare provider about any pre-existing conditions or medications you are taking before starting treatment.

CORIFACT 250 may interact with other medications, particularly those that affect blood clotting. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol consumption should be avoided as it can interfere with the medication's effectiveness. Always consult a healthcare provider for personalized advice on managing potential interactions.